You’ve decided to stop your GLP-1 medication — or your insurance stopped covering it. Either way, you’re wondering: what happens now?
The data is sobering. The STEP 1 extension trial showed that participants who stopped semaglutide regained approximately two-thirds of their lost weight within one year. A Cambridge meta-analysis across multiple GLP-1 trials confirmed similar patterns.
But “average regain” is not your destiny. Understanding what’s happening in your body week by week gives you a real advantage. Here’s the timeline.
Weeks 1–2: The Water Weight Phase
What’s happening: Your body is restoring glycogen and water — not gaining fat.
When you stop a GLP-1 medication, two things change immediately. First, the drug’s effect on gastric emptying fades, so food moves through your system faster. Second, your body begins replenishing glycogen stores in your muscles and liver. Every gram of glycogen binds roughly 3 grams of water.
The scale will likely jump 1–3 kg (2–7 lbs) in the first two weeks. This is not fat gain. It’s your body rehydrating.
What to do: Keep weighing yourself, but understand the number. Write down “glycogen rebound” and move on. Panicking here leads to bad decisions.
Weeks 3–4: Appetite Returns
What’s happening: GLP-1 receptors in your brain are reactivating baseline hunger signals.
This is the phase most people underestimate. Semaglutide and tirzepatide work partly by acting on GLP-1 receptors in the hypothalamus, suppressing appetite at a neurological level. When the drug clears your system (half-life is approximately 7 days for semaglutide), those receptors gradually return to their pre-medication sensitivity.
You may experience:
- Noticeably increased hunger, especially in the evening
- Return of food-focused thoughts
- Cravings for high-calorie foods you hadn’t thought about in months
- Reduced satiety from the same portion sizes
This is not a failure of willpower. It’s pharmacology. Your brain’s appetite regulation is literally resetting.
What to do: Maintain the eating patterns you built on the medication — protein-first meals, consistent timing, planned portions. Structure replaces the drug’s appetite suppression.
Weeks 5–8: The Stabilization Window
What’s happening: Your metabolism is adjusting to a new energy balance.
This is the critical period. Your body is recalibrating its energy expenditure. If you lost significant lean muscle mass during treatment (common without adequate protein and resistance training), your resting metabolic rate may be lower than before you started the medication.
Weight changes during this phase are more meaningful than weeks 1–4 because they reflect actual tissue changes rather than fluid shifts.
What to do:
- Resistance training 2–3 times per week is the single most impactful intervention. Muscle is metabolically active tissue.
- Protein intake should remain at 1.2–1.5 g/kg/day. Don’t relax this.
- Sleep 7–9 hours. Sleep deprivation increases ghrelin (hunger hormone) by up to 28%.
- Track your weight at the same time daily and look at the 7-day rolling average, not daily fluctuations.
Weeks 9–12: New Baseline Establishing
What’s happening: Your body is settling into its post-medication equilibrium.
By week 9, most of the acute pharmacological withdrawal effects have resolved. Your appetite has found its new normal. Your weight trajectory over this month is a strong predictor of where you’ll land at 6 and 12 months.
The STEP 1 extension data shows that the trajectory established in this window — gaining, maintaining, or still losing — tends to continue. This is where structured daily habits either lock in or erode.
What to do: Evaluate honestly. If your 7-day average weight is stable or slowly trending down, your habits are working. If it’s climbing steadily, consider what specific behavior changed and address it.
What “Structured Support” Actually Means
You’ll hear this term in clinical literature. It means having systems in place that replace what the medication was doing for you:
- Daily tracking — weight, protein, activity (30 seconds is enough)
- Pattern recognition — identifying which days and situations lead to overconsumption
- Accountability — whether through an app, a coach, or a partner
- Early intervention — catching a 2 kg upward trend at week 3, not a 10 kg regain at month 6
Check Your Rebound Risk
Everyone’s risk profile is different. Factors include how long you were on the medication, how much weight you lost, your current muscle mass, and your daily habits.
Our Rebound Risk Calculator uses clinical data from STEP 1 and SURMOUNT-1 to estimate your personal regain risk and identify which factors you can modify.
Sources:
- Wilding, J.P.H. et al. “Weight Regain and Cardiometabolic Effects After Withdrawal of Semaglutide.” Diabetes, Obesity and Metabolism, 2022 (STEP 1 Extension).
- Jastreboff, A.M. et al. “SURMOUNT-1 Trial Results.” NEJM, 2022.
- Sargeant, J.A. et al. “A Systematic Review of Weight Regain After Anti-Obesity Medication Discontinuation.” Cambridge University Press, 2024.
- Spiegel, K. et al. “Sleep and Ghrelin Levels.” Annals of Internal Medicine, 2004.
This article is for informational purposes only and does not constitute medical advice. Never stop or adjust your GLP-1 medication without consulting your healthcare provider.